We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





Sebia Showcases HbA1c Testing Solutions for Every Size Laboratory at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022
Print article
Image: Sebia provides a solution for every size laboratory for HbA1c testing (Photo courtesy of Sebia)
Image: Sebia provides a solution for every size laboratory for HbA1c testing (Photo courtesy of Sebia)

Sebia (Lisses, France) is showcasing its wide portfolio of instruments and tests designed to address clinical needs and improve laboratory efficiency and safety at the 2022 AACC Clinical Lab Expo. From the lowest to the highest volumes, with standalone instruments to workcell configurations, Sebia will highlight various solutions for laboratories at the event.

At AACC 2022, Sebia is demonstrating the CAPILLARYS 3 TERA MC high throughput capillary electrophoresis system that allows the combination of one to three CAPILLARYS 3 TERA instruments to a Sebia loader, with a loading capacity of 528 samples in one row. This high volume workcell provides three hours autonomy on HbA1c, and hemoglobin testing, and more than two hours on proteins, processing up to 528 samples in one go. The system can be fed continuously with additional racks, and the reagent management system allows ad-hoc reagent addition at any time, without interruption. Sebia also highlighted its portfolio of tests from multiple myeloma to metabolic disorders, hemoglobinopathies and genetic diseases.

In addition, Sebia will showcase its fully automated, random access Alegria 2 ELISA platform with its comprehensive menu of antigen assays & panels utilizing a unique Monotest strip technology that allows serum, plasma, and fecal sample testing in the same run. Visitors to the company’s AACC 2022 booth can learn about Phoresis CORE, the unified software solution for labs utilizing Sebia instruments which offers traceable patient sampling from reagent to result, remote interpretation in real-time, from anywhere, and with comprehensive patient history for all of its assays. Visitors can also learn how labs can partner with the company for its Sebia Workflow Service to maximize automation, reduce errors, and improve workflow.
 

Related Links:
Sebia 

New
Gold Supplier
Influenza Type A & B Test
Influenza A+B DUO
New
Isothermal Microfluidic Chip Analyzer
CapitalBio RTisochip
New
COL-R Assay
CHROMagar COL-APSE
New
Cancer Rapid Diagnostic Test
Xpert Breast Cancer STRAT4

Print article

Channels

Molecular Diagnostics

view channel
Image: The new multiplex QIAstat-Dx Viral Vesicular Panel is designed to support research and surveillance efforts (Photo courtesy of QIAGEN)

First Syndromic Test Differentiates Between Monkeypox and Five Pathogens with Similar Symptoms

A new syndromic test differentiates between monkeypox and five other pathogens which cause similar symptoms. This first-ever test detects the two known forms of monkeypox virus (the so-called West African... Read more

Industry

view channel
Image: The Accelerate Arc Module & BC kit is registered as an IVD (Photo courtesy of Accelerate Diagnostics)

BD and Accelerate Diagnostics Collaborate to Offer Rapid Antimicrobial Identification and Susceptibility Diagnostics

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) and Accelerate Diagnostics, Inc. (Tucson, AZ, USA) have entered into a worldwide commercial collaboration agreement where BD will offer Accelerate's... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.